MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: Novel Lung Cancer Vaccine Trial Launched

Back to lung cancer blog Blogs list Cancer blog  


Subscribe To Lung Cancer Blog RSS Feed  RSS content feed What is RSS feed?

Novel Lung Cancer Vaccine Trial Launched




Oncologists at the Moores Cancer Center at the University of California, San Diego (UCSD) in La Jolla are hoping to stave off the relentless march of advanced lung cancer by treating patients with a novel kind of cancer vaccine. While a number of vaccines attempt to pump up the immune system to fight off a cancer, the new vaccine, Lucanix, is genetically engineered to also trick the cancer into turning off its immune system-suppressing activities.

The first patients have begun enrolling in a new clinical trial at the Moores UCSD Cancer Center testing the effectiveness of the vaccine. The trial will involve 700 patients at some 90 centers worldwide.



Novel Lung Cancer Vaccine Trial Launched

Current therapys for advanced lung cancer have limited effectiveness and new therapies are needed, said Lyudmila Bazhenova, M.D., director of the Lung Cancer Unit at the Moores UCSD Cancer Center and assistant clinical professor of medicine at UC San Diego School of Medicine.

"The future therapys for advanced lung cancer may involve combinations of chemotherapy and targeted agents, and possibly even biologicals such as this," she said.

Roughly 430 patients die of lung cancer every day in the United States, as per Bazhenova, making it the nation's number one killer, despite being the second most common cancer. "While breast cancer mortality has declined about 15 percent, there hasn't been much improvement in mortality in lung cancer in the past several decades," she said. As per the American Cancer Society, an estimated 215,000 new cases of lung cancer will be diagnosed, and 162,000 individuals will die from the disease this year in the United States.

The vaccine, developed by NovaRx, a biopharmaceutical company based in San Diego, consists of lung cancer cells that have been genetically altered to shut down the cancer's ability to depress the immune system. In addition, the cells are also modified to enable the immune system to see them better.

Bazhenova explained that earlier tests of the vaccine's effectiveness produced encouraging results. The current trial is for patients with stage four non-small cell lung cancer who have completed four to six cycles of platinum-based chemotherapy. Those patients who have had a response to the therapy, meaning either tumor shrinkage or stable disease, may be eligible. The trial is a double-blind, placebo-controlled study, where neither patients nor doctors know who is getting the vaccine and who may be receiving a placebo. Patients receive injections once a month for 18 months, after which they receive two quarterly injections and are treated until disease progression. The trial's main goal is to determine if the vaccine can improve patient survival in comparison to taking placebo.


Posted by: Scott    Source




Did you know?
Oncologists at the Moores Cancer Center at the University of California, San Diego (UCSD) in La Jolla are hoping to stave off the relentless march of advanced lung cancer by treating patients with a novel kind of cancer vaccine. While a number of vaccines attempt to pump up the immune system to fight off a cancer, the new vaccine, Lucanix, is genetically engineered to also trick the cancer into turning off its immune system-suppressing activities.

Medicineworld.org: Novel Lung Cancer Vaccine Trial Launched

Main Page| Cancer blog| Cancer blogs list| Lung cancer blog| Colon cancer blog| Prostate cancer blog| Breast cancer blog| Diabetes watch blog| Heart watch blog| Allergy blog| Bladder cancer blog| Cervical cancer blog| Colon cancer news blog| Diabetes news blog| Esophageal cancer blog| Gastric cancer blog| Health news blog| Heart news blog| Infectious disease blog| Kidney watch blog| Lung disease blog| Lung cancer news blog| Mesothelioma blog| Neurology blog| Breast cancer news blog| OBGYN blog| Ophthalmology blog| Ovarian cancer blog| Cancer news blog| Pancreas cancer blog| Pediatrics blog| Prostate cancer news blog| Psychology blog| Research blog| Rheumatology blog| Society news blog| Uterine cancer blog| Weight watch blog|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.